9JU1
Helix-loop-helix peptide (VS42-LR3) in complex with VEGF-A
9JU1 の概要
| エントリーDOI | 10.2210/pdb9ju1/pdb |
| 分子名称 | VS42-LR3, Vascular endothelial growth factor A, long form, SULFATE ION, ... (4 entities in total) |
| 機能のキーワード | helix-loop-helix, inhibitor, complex, de novo protein, immune system-de novo protein complex, immune system/de novo protein |
| 由来する生物種 | Homo sapiens (human) 詳細 |
| タンパク質・核酸の鎖数 | 2 |
| 化学式量合計 | 16784.15 |
| 構造登録者 | Kamo, M.,Michigami, M.,Inaka, K.,Furubayashi, N.,Kaito, S.,Kobayashi, Y.,Shinohara, Y.,Fujii, I. (登録日: 2024-10-07, 公開日: 2024-12-25) |
| 主引用文献 | Michigami, M.,Notsu, K.,Kamo, M.,Hirokawa, T.,Kinoshita, T.,Inaka, K.,Nakase, I.,Fujii, I. Structural insights into molecular-targeting helix-loop-helix peptide against vascular endothelial growth factor-A. Biochem Biophys Res Commun, 734:150749-, 2024 Cited by PubMed Abstract: Mid-sized binding peptides have recently emerged as a new therapeutic modality. A helix-loop-helix (HLH) peptide was designed as a scaffold for combinatorial peptide libraries. We screened the HLH peptide libraries against human vascular endothelial growth factor-A (VEGF) to generate a peptide, VS42-LR3, which inhibited VEGF/receptor interaction and suppressed tumor growth in a murine xenograft model of human colorectal cancer. Here, we report the first crystal structure of the HLH peptide in a complex with VEGF at high resolution using space-grown protein crystals. The X-ray structural analysis revealed that the monomeric VS42-LR3 adopted an HLH structure and bound to VEGF at the VEGF receptor-binding site. Interestingly, from the site-directed mutagenesis, thermodynamic analysis, and molecular dynamic simulations, it turned out that the loop region in the non-interacting surface to VEGF affected the structural rigidity of the whole HLH to increase the binding affinity. These findings provide valuable insights for the design of more structurally stable and higher affinity mid-sized binding peptides as well as HLH peptides, that could play a crucial role in advancing molecular-targeting therapies. PubMed: 39357335DOI: 10.1016/j.bbrc.2024.150749 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (1.45 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






